Human papillomavirus infection with multiple types: Pattern of coinfection and risk of cervical disease

Journal of Infectious Diseases

Volumn 203, Issue 7, 2011, Pages 910-920

  Chaturvedi, Anil K ^a   Katki, Hormuzd A ^a   Hildesheim, Allan ^a   Rodríguez, Ana Cecilia ^b   Quint, Wim ^c   Schiffman, Mark ^a   Van Doorn, Leen Jan ^c   Porras, Carolina ^b   Wacholder, Sholom ^a   Gonzalez, Paula ^b   Sherman, Mark E ^a   Herrero, Rolando ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^c DDL DIAGNOSTIC LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; WART VIRUS VACCINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONDYLOMA; CONTROLLED STUDY; COSTA RICA; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; GENOTYPE; HUMAN; INFECTION RISK; MIXED INFECTION; PHYLOGENY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; UTERINE CERVIX DISEASE; VACCINATION; WART VIRUS;

ADOLESCENT; ADULT; CERVIX UTERI; COSTA RICA; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; INCIDENCE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK ASSESSMENT; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 79953005484     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq139     Document Type: Article

References (29)

1. Vaccarella S, Franceschi S, Snijders PJ, Herrero R, Meijer CJ, Plummer M. Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev 2010; 19:503-10.
2. Thomas KK, Hughes JP, Kuypers JM, et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000; 182:1097-102.
3. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183:8-15. (Pubitemid 32043036)
4. Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 2001; 184:1508-17. (Pubitemid 33139735)
5. Chaturvedi AK, Myers L, Hammons AF, et al. Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections. Cancer Epidemiol Biomarkers Prev 2005; 14:2439-45. (Pubitemid 41437849)
6. Mendez F, Munoz N, Posso H, et al. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis 2005; 192:1158-65. (Pubitemid 41368414)
7. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195:1582-9. (Pubitemid 46799215)
8. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27.
9. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009; 2:868-78.
10. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14.
11. Rousseau MC, Abrahamowicz M, Villa LL, Costa MC, Rohan TE, Franco EL. Predictors of cervical coinfection with multiple human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2003; 12:1029-37. (Pubitemid 37310259)
12. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70. (Pubitemid 46977438)
13. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009; 199:936-44.
14. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199:926-35.
15. Herrero R. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis 2009; 199:919-22.
16. Wentzensen N, Schiffman M, Dunn T, et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer 2009; 125:2151-8.
17. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005; 191:1796-807. (Pubitemid 40705385)
18. Trottier H, Mahmud S, Costa MC, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006; 15:1274-80. (Pubitemid 44125281)
19. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324:17-27.
20. Herrero R, Hildesheim A, Rodriguez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008; 26:4795-808.
21. Van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006; 44:3292-8. (Pubitemid 44413767)
22. Assmann SF, Hosmer DW, Lemeshow S, Mundt KA. Confidence intervals for measures of interaction. Epidemiology 1996; 7:286-90. (Pubitemid 26120376)
23. Winer RL, Lee SK, Hughes JP, AdamDE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157:218-26. (Pubitemid 36152435)
24. Koshiol J, Schroeder J, Jamieson DJ, et al. Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women. Am J Epidemiol 2006; 164:176-83. (Pubitemid 43992184)
25. Xi LF, Koutsky LA, Castle PE, et al. Relationship between cigarette smoking and human papilloma virus types 16 and 18 DNA load. Cancer Epidemiol Biomarkers Prev 2009; 18:3490-6.
26. Rousseau MC, Villa LL, Costa MC, Abrahamowicz M, Rohan TE, Franco E. Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Sex Transm Dis 2003; 30:581-7. (Pubitemid 36828984)
27. Xi LF, Edelstein ZR, Meyers C, Ho J, Cherne SL, Schiffman M. Human papillomavirus types 16 and 18 DNA load in relation to coexistence of other types, particularly those in the same species. Cancer Epidemiol Biomarkers Prev 2009; 18:2507-12.
28. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008; 109(Suppl 2);21.
29. Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008; 26(Suppl 10);61.